Unknown

Dataset Information

0

Post-Induction Treatment for Acute Myeloid Leukemia: Something Change?


ABSTRACT:

Purpose of review

Until recently, improvement in terms of survival for patients with acute myeloid leukemia (AML) was achieved mostly in younger patients with dose intensification of conventional chemotherapy and a broadening use of allogeneic hematopoietic cell transplantation (allo-HCT) whereas the results remained dismal and very stable in patients older than 60 years. The current review highlights the recent developments in standard intensive post-remission chemotherapy, evidence for the use of recently approved agents, and discusses the relevance of measurable residual disease (MRD) measurement in treatment adaptation.

Recent findings

Current approvals of midostaurin, venetoclax, gemtuzumab ozogamicin, VYXEOS, ivosidenib, enasidenib, glasdegib, and CC-486 have changed the structure, aim, and schedule of consolidation therapy, and new, well-tolerated agents are being evaluated as maintenance therapies. Furthermore, MRD assessment has been implemented to guide the duration and type of consolidation and maintenance therapy as well as indicate the optimal timing of allo-HCT. Novel therapies have changed the structure and perspective of post-remission therapy in AML for both young and elderly patients. In addition, MRD assessment could guide the type, duration, and intensity of consolidation and maintenance therapy.

SUBMITTER: Jaramillo S 

PROVIDER: S-EPMC8285306 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC7762084 | biostudies-literature
| S-EPMC10927218 | biostudies-literature
| S-EPMC7324428 | biostudies-literature
| S-EPMC7573974 | biostudies-literature
| S-EPMC3301423 | biostudies-literature
| S-EPMC8171365 | biostudies-literature
| S-EPMC8759116 | biostudies-literature
| S-EPMC56962 | biostudies-literature
| S-EPMC4691220 | biostudies-literature
| S-EPMC7188377 | biostudies-literature